Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

DXR vs DBVT vs ALKS vs TFX vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DXR
Daxor Corporation

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$56M
5Y Perf.-27.5%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
TFX
Teleflex Incorporated

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$5.83B
5Y Perf.-63.7%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+63.2%

DXR vs DBVT vs ALKS vs TFX vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DXR logoDXR
DBVT logoDBVT
ALKS logoALKS
TFX logoTFX
INVA logoINVA
IndustryMedical - Instruments & SuppliesBiotechnologyBiotechnologyMedical - Instruments & SuppliesBiotechnology
Market Cap$56M$1712.35T$5.90B$5.83B$1.93B
Revenue (TTM)$868K$0.00$1.56B$2.81B$424M
Net Income (TTM)$3M$-168M$153M$-1.01B$504M
Gross Margin91.4%65.4%53.3%76.2%
Operating Margin5.4%12.3%5.6%14.8%
Forward P/E87.8x24.8x19.6x11.9x
Total Debt$730K$22M$70M$2.73B$269M
Cash & Equiv.$194M$1.12B$393M$551M

DXR vs DBVT vs ALKS vs TFX vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DXR
DBVT
ALKS
TFX
INVA
StockMay 20May 26Return
Daxor Corporation (DXR)10072.5-27.5%
DBV Technologies S.… (DBVT)10041.2-58.8%
Alkermes plc (ALKS)100216.4+116.4%
Teleflex Incorporat… (TFX)10036.3-63.7%
Innoviva, Inc. (INVA)100163.2+63.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: DXR vs DBVT vs ALKS vs TFX vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Daxor Corporation is the stronger pick specifically for profitability and margin quality. DBVT and TFX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
DXR
Daxor Corporation
The Income Pick

DXR is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 0 yrs, beta 0.33
  • 401.5% margin vs TFX's -35.9%
Best for: income & stability
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +110.4% vs TFX's +9.0%
Best for: momentum
ALKS
Alkermes plc
The Quality Angle

Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.

Best for: healthcare exposure
TFX
Teleflex Incorporated
The Income Pick

TFX is the clearest fit if your priority is dividends.

  • 1.0% yield; the other 4 pay no meaningful dividend
Best for: dividends
INVA
Innoviva, Inc.
The Growth Play

INVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
  • 94.9% 10Y total return vs DXR's 21.9%
  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • Beta 0.13, current ratio 14.64x
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthINVA logoINVA18.5% revenue growth vs DBVT's -100.0%
ValueINVA logoINVALower P/E (11.9x vs 19.6x)
Quality / MarginsDXR logoDXR401.5% margin vs TFX's -35.9%
Stability / SafetyINVA logoINVABeta 0.13 vs DBVT's 1.26
DividendsTFX logoTFX1.0% yield; the other 4 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs TFX's +9.0%
Efficiency (ROA)INVA logoINVA32.4% ROA vs DBVT's -89.0%

DXR vs DBVT vs ALKS vs TFX vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DXRDaxor Corporation

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
TFXTeleflex Incorporated
FY 2025
Vascular Access
46.1%$918M
Interventional
32.5%$648M
Surgical
21.0%$418M
Other
0.5%$9M
INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

DXR vs DBVT vs ALKS vs TFX vs INVA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINVALAGGINGTFX

Income & Cash Flow (Last 12 Months)

DXR leads this category, winning 3 of 6 comparable metrics.

TFX and DBVT operate at a comparable scale, with $2.8B and $0 in trailing revenue. DXR is the more profitable business, keeping 4.0% of every revenue dollar as net income compared to TFX's -35.9%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$867,859$0$1.6B$2.8B$424M
EBITDAEarnings before interest/tax$7M-$112M$212M$280M$86M
Net IncomeAfter-tax profit$3M-$168M$153M-$1.0B$504M
Free Cash FlowCash after capex-$5M-$151M$392M$249M$181M
Gross MarginGross profit ÷ Revenue+91.4%+65.4%+53.3%+76.2%
Operating MarginEBIT ÷ Revenue+5.4%+12.3%+5.6%+14.8%
Net MarginNet income ÷ Revenue+4.0%+9.8%-35.9%+118.9%
FCF MarginFCF ÷ Revenue-5.4%+25.1%+8.9%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year-74.4%+28.2%-21.8%+10.6%
EPS Growth (YoY)Latest quarter vs prior year+78.2%+91.5%-4.1%-108.7%+4.0%
DXR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

INVA leads this category, winning 3 of 6 comparable metrics.

At 6.9x trailing earnings, INVA trades at a 92% valuation discount to DXR's 87.8x P/E. On an enterprise value basis, INVA's 8.1x EV/EBITDA is more attractive than DXR's 27.7x.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
Market CapShares × price$56M$1712.35T$5.9B$5.8B$1.9B
Enterprise ValueMkt cap + debt − cash$57M$1712.35T$4.9B$8.2B$1.7B
Trailing P/EPrice ÷ TTM EPS87.82x-0.76x24.76x-6.50x6.91x
Forward P/EPrice ÷ next-FY EPS est.19.59x11.91x
PEG RatioP/E ÷ EPS growth rate0.67x
EV / EBITDAEnterprise value multiple27.70x17.25x18.82x8.10x
Price / SalesMarket cap ÷ Revenue26.42x4.00x2.93x4.55x
Price / BookPrice ÷ Book value/share1.31x0.66x3.28x1.88x1.65x
Price / FCFMarket cap ÷ FCF2190.99x12.28x23.75x9.88x
INVA leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 4 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. DXR carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TFX's 0.87x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity+10.1%-130.2%+8.8%-28.3%+46.5%
ROA (TTM)Return on assets+9.8%-89.0%+5.4%-13.9%+32.4%
ROICReturn on invested capital+1.3%+18.9%+3.4%+14.2%
ROCEReturn on capital employed+1.7%-145.7%+14.2%+4.0%+12.4%
Piotroski ScoreFundamental quality 0–954755
Debt / EquityFinancial leverage0.02x0.13x0.04x0.87x0.23x
Net DebtTotal debt minus cash$729,966-$172M-$1.0B$2.3B-$282M
Cash & Equiv.Liquid assets$194M$1.1B$393M$551M
Total DebtShort + long-term debt$729,966$22M$70M$2.7B$269M
Interest CoverageEBIT ÷ Interest expense-6.11x-189.82x32.30x-2.02x63.45x
ALKS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

INVA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs TFX's +9.0%. The 3-year compound annual growth rate (CAGR) favors INVA at 25.0% vs TFX's -19.4% — a key indicator of consistent wealth creation.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date-32.7%+4.9%+25.3%+7.9%+14.7%
1-Year ReturnPast 12 months+29.3%+110.4%+16.5%+9.0%+21.7%
3-Year ReturnCumulative with dividends-17.8%+19.7%+14.5%-47.6%+95.2%
5-Year ReturnCumulative with dividends+3.3%-69.1%+60.9%-66.4%+94.4%
10-Year ReturnCumulative with dividends+21.9%-87.0%-11.0%-10.3%+94.9%
CAGR (3Y)Annualised 3-year return-6.3%+6.2%+4.6%-19.4%+25.0%
INVA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DXR's 65.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5000.33x1.26x1.06x1.06x0.13x
52-Week HighHighest price in past year$14.76$26.18$36.60$139.63$25.15
52-Week LowLowest price in past year$7.13$7.53$25.17$100.18$16.52
% of 52W HighCurrent price vs 52-week peak+65.4%+76.3%+96.7%+94.3%+90.7%
RSI (14)Momentum oscillator 0–10048.048.160.248.539.9
Avg Volume (50D)Average daily shares traded11K252K2.3M884K621K
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy", TFX as "Buy", INVA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 0.4% for TFX (target: $132). TFX is the only dividend payer here at 1.02% yield — a key consideration for income-focused portfolios.

MetricDXR logoDXRDaxor CorporationDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTFX logoTFXTeleflex Incorpor…INVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$46.33$44.00$132.20$37.67
# AnalystsCovering analysts15282910
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises00000
Dividend / ShareAnnual DPS$1.35
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%+5.1%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

INVA leads in 2 of 6 categories (Valuation Metrics, Total Returns). DXR leads in 1 (Income & Cash Flow). 1 tied.

Best OverallInnoviva, Inc. (INVA)Leads 2 of 6 categories
Loading custom metrics...

DXR vs DBVT vs ALKS vs TFX vs INVA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DXR or DBVT or ALKS or TFX or INVA a better buy right now?

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -93. 8% for Daxor Corporation (DXR). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DXR or DBVT or ALKS or TFX or INVA?

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Daxor Corporation at 87. 8x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.

03

Which is the better long-term investment — DXR or DBVT or ALKS or TFX or INVA?

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: INVA returned +94. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DXR or DBVT or ALKS or TFX or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 897% more volatile than INVA relative to the S&P 500. On balance sheet safety, Daxor Corporation (DXR) carries a lower debt/equity ratio of 2% versus 87% for Teleflex Incorporated — giving it more financial flexibility in a downturn.

05

Which is growing faster — DXR or DBVT or ALKS or TFX or INVA?

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -93. 8% for Daxor Corporation (DXR). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DXR or DBVT or ALKS or TFX or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — DXR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DXR or DBVT or ALKS or TFX or INVA more undervalued right now?

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 9x forward P/E versus 19. 6x for Teleflex Incorporated — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — DXR or DBVT or ALKS or TFX or INVA?

In this comparison, TFX (1.

0% yield) pays a dividend. DXR, DBVT, ALKS, INVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is DXR or DBVT or ALKS or TFX or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DXR and DBVT and ALKS and TFX and INVA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DXR is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; TFX is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. TFX pays a dividend while DXR, DBVT, ALKS, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DXR

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 240%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

TFX

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.